Adalimumab
Brand: Humira / Exemptia / Hyrimoz
Class: Immunomodulator
Subclass: TNF-alpha inhibitor (human mAb)
PK:
t½ 14 days | Clearance: reticuloendothelial
Max Dose: not added
severe
AE: Injection-site reactions, serious infections (TB, fungal), malignancy risk (lymphoma), hepatitis B reactivation, cytopenias